Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 22, 2023 - Issue 1
Submit an article Journal homepage
2,307
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Can COVID-19 have a clinically significant effect on drug metabolism?

Felicia Cebana Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada;b Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada;c Brain and Cognition Discovery Foundation, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0001-6815-7248View further author information
ORCID Icon,
Mehala Subramaniapillaia Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, CanadaView further author information
,
Joshua D. Rosenblata Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada;d Department of Psychiatry, University of Toronto, Toronto, ON, Canada;e Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, CanadaView further author information
,
Rodrigo B. Mansura Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada;d Department of Psychiatry, University of Toronto, Toronto, ON, CanadaView further author information
&
Roger S. McIntyrea Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada;c Brain and Cognition Discovery Foundation, Toronto, ON, Canada;d Department of Psychiatry, University of Toronto, Toronto, ON, Canada;e Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
View further author information
Pages 1-3 | Received 18 Aug 2022, Accepted 19 Jan 2023, Published online: 05 Feb 2023

References

  • Ritter JM, Flower RJ, Henderson G, et al. Rang and Dale’s Pharmacology. Elsevier; 2019.
  • Whalen K. Lippincott® illustrated reviews: pharmacology. Wolters Kluwer India Pvt Ltd; 2018.
  • Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 2001;92(2–3):147–163.
  • Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434–438.
  • Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation [Internet]. Annu Rev Pharmacol Toxicol. 2006;46(1):123–149. Available from.
  • Haack MJ, Bak MLFJ, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13(5):381–385.
  • Mallick P, Taneja G, Moorthy B, et al. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions. Expert Opin Drug Metab Toxicol. 2017;13(6):605–616.
  • Nicholson TE, Renton KW. The role of cytokines in the depression of CYP1A activity using cultured astrocytes as an in vitro model of inflammation in the central nervous system. Drug Metab Dispos. 2002;30(1):42–46.
  • Renton KW, Dibb S, Levatte TL. Lipopolysaccharide evokes the modulation of brain cytochrome P4501A in the rat. Brain Res. 1999;842(1):139–147.
  • Lenoir C, Rollason V, Desmeules JA, et al. Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature. Front Pharmacol. 2021;12:733935.
  • Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87(3):277–280.
  • Li H, Clarke JD, Dzierlenga AL, et al. In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. J Biochem Mol Toxicol. [Internet]. 2017;31. Available from.;2:e21840. http://dx.doi.org/10.1002/jbt.21840
  • Gravel S, Chiasson J-L, Turgeon J, et al. Modulation of CYP 450 activities in patients with type 2 diabetes. Clin Pharmacol Ther. 2019;106(6):1280–1289.
  • White CM, Michael White C. Inflammation suppresses patients’ ability to metabolize cytochrome P450 substrate drugs [Internet]. Ann Pharmacother. 2022;56(7):809–819.
  • Fajgenbaum DC, June CH, Storm C, et al. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273.
  • Jothimani D, Venugopal R, Abedin MF, et al. COVID-19 and the liver. J Hepatol. 2020;73(5):1231–1240.
  • El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses. 2020;144:110033.
  • Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168(4):1057–1059.
  • Polakos NK, Cornejo JC, Murray DA, et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol. 2006;168(4):1169–1178. quiz 1404–1405.
  • Deb S, Arrighi S. Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients. Eur J Drug Metab Pharmacokinet. 2021;46(2):185–203.
  • Wang G, Xiao B, Deng J, et al. The role of cytochrome P450 enzymes in COVID-19 pathogenesis and therapy. Front Pharmacol. 2022;13:791922.
  • Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93–135.
  • Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.
  • Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–216.
  • Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis [Internet]. 2021;22(4):e102–e107.
  • Ceban F, Leber A, Jawad MY, et al. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect Dis. 2022;54(7):1–11.
  • Canadian Institutes of Health Research. Detailed information [Internet]. [cited 2022 Aug 9]. Available from: https://webapps.cihr-irsc.gc.ca/funding/detail_e?pResearchId=9790549&p_version=CIHR&p_language=E&p_session_id=3266369.
  • Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry [Internet]. 2021 [cited 2021 Sep 22]; 78(10):1079. Available from: https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2782453

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.